Eurosurv. International external quality assessment for SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVI

[tetano]

• International external quality assessment for SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-19 pandemic, April/May 2020
  
  
• Veerle Matheeussen[SUP]1,6[/SUP] , Victor M Corman[SUP]2,6[/SUP] , Oliver Donoso Mantke[SUP]3,6[/SUP] , Elaine McCulloch[SUP]3[/SUP] , Christine Lammens[SUP]1[/SUP] , Herman Goossens[SUP]1[/SUP] , Daniela Niemeyer[SUP]2[/SUP] , Paul S Wallace[SUP]3[/SUP] , Paul Klapper[SUP]4[/SUP] , Hubert GM Niesters[SUP]5[/SUP] , Christian Drosten[SUP]2[/SUP] , Margareta Ieven[SUP]1[/SUP] , on behalf of the RECOVER project and collaborating networks[SUP]7[/SUP]

Laboratory preparedness with quality-assured diagnostic assays is essential for controlling the current coronavirus disease (COVID-19) outbreak. We conducted an external quality assessment study with inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) samples to support clinical laboratories with a proficiency testing option for molecular assays. To analyse SARS-CoV-2 testing performance, we used an online questionnaire developed for the European Union project RECOVER to assess molecular testing capacities in clinical diagnostic laboratories.

full article

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.27.2001223#html_fulltext